Welcome to Critical MassLaw.com’s weekly briefing for class action and mass tort attorneys. This week, it’s all about settlements: What does Purdue’s $270 million settlement mean for the rest of the opioid litigation? Find out which cases are excluded from the Xarelto settlement. And a new report finds that the value of securities class action settlements surged in 2018.

Send your feedback to [email protected], or find me on Twitter: @abronstadlaw.

What’s Next for Opioid Cases After Purdue Pharma’s Settlement With Oklahoma?

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]